SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around recent developments and listings, emphasizing its status as a survivor meme on the Solana blockchain. The focus is on community support, long-term growth, and upcoming developments, with many highlighting it as a coin with strong potential. Community members are actively promoting the coin's unique attributes and encouraging others to join, emphasizing the project's commitment to the community.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is gaining traction, with community members actively discussing potential breakouts and significant moves. Talk centers around the coin's strong momentum, fueled by new listings and a push towards multichain expansion. Investors are closely watching for further upward movement, with some suggesting that the frog-themed meme coin may outperform others in its category.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies behind this Solana-based meme coin, celebrating its locked liquidity and long-term development. Many are drawn to its strong community, joke-meta pioneer status, and its listing on Jupiter Strict List. The crypto is also gaining traction as social media users ask, 'What's UpDog?'

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is gaining attention as social media buzz points to a potential breakout, with the community noting positive chart patterns. The crypto is being discussed alongside other popular cryptocurrencies, indicating heightened interest. Investors are focused on potential early entry opportunities as the token gains momentum.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

MAMO.X is trending as the community discusses its potential, drawing comparisons to previous successes like AERO.X. Bullish sentiment is fueled by anticipation of the Base App launch and potential exposure to millions of new users. Some traders are suggesting that it is a potential buying opportunity, while others are expressing concerns about the recent price action.

USELESS

$USELESS.X is trending as community members rally behind its self-deprecating name, embracing the humor while highlighting potential for massive gains. Talk centers around the meme coin's potential to reach a billion-dollar market cap, with some suggesting even higher targets during the current bull run. Despite its branding, some are drawn to the project due to its listings on major exchanges and community-driven approach.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members discussing its potential, links to price predictions, and possible movement into AI. Some traders are comparing it to other meme coins like $PEPE.X, $UPDOG.X, and $PUPU.X while also debating its long-term viability and burn rate.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is gaining attention, with community members noting a steady climb and breakout potential. Conversations highlight positive momentum, strong vibes, and a potential pump, with many encouraging others to buy in early via Phantom Wallet. Some users are also pointing to a connection with the $UPDOG.X token.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as users discuss the timeline for unverified balances to become available and speculate on potential listings on major exchanges. The community is also debating the project's long-term potential and real-world utility, with some expressing concerns about dilution and lack of access in certain regions, while others remain optimistic and continue to mine.

Aventus Network

Aventus Network ($AVT.X) is trending as traders discuss its potential for a breakout, citing its low market cap and integration with Polkadot. Community members highlight real-world partnerships and a strong chart setup, anticipating significant price movement with increased volume. Some are comparing $AVT.X to other trending coins, noting the potential for substantial gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is doubling down on its mission to revolutionize cancer treatment with radiation therapy. In just a few short weeks, the company has achieved a series of notable milestones, from a promising Phase 2 trial update to the appointment of veteran biotech executive George Scorsis as Chairman of the Board.With its lead candidate Ropidoxuridine already making waves in glioblastoma trials, Shuttle Pharma is positioning itself at the forefront of oncology innovation. The moves come as Shuttle looks to emulate recent breakthroughs by industry leaders such as <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/lantheus-holdings/">Lantheus Holdings (NASDAQ: LNTH)</a> and <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/novartis/">Novartis (NYSE: NVS)</a>, both of which have brought radiopharmaceutical therapies to market using similar underlying science.<h3>George Scorsis Steps In as Chairman</h3>On Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">Shuttle Pharma announced</a> George Scorsis as the new Chairman of its Board of Directors. Scorsis brings over 25 years of executive experience, particularly in highly regulated sectors including biotech and cannabis. His resume includes leadership roles at Liberty Health Sciences and Mettrum Health Corp., and he currently chairs both <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/awakn-life-sciences">Awakn Life Sciences (CSE: AWKN) (OTCQB: AWKNF)</a> and Entourage Health Corp.Commenting on <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-appoints-george-scorsis-chairman-of-the-board-of-directors/">his new role</a> at Shuttle, Scorsis stated:<blockquote>I am honored to take on the role of Chairman of Shuttle Pharma. The Company has a unique opportunity to leverage its radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma. I look forward to providing guidance to support the Company as we look to improve the lives of millions of patients impacted by cancer.</blockquote>Scorsis also previously served as Chairman of <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/sol-global-investments">SOL Global Investments (CSE: SOL) (OTC: SOLCF)</a>, which further illustrates his deep involvement in pioneering healthcare ventures.His appointment reflects Shuttle’s strategic push to strengthen its leadership team as it enters a pivotal period of clinical and commercial development.<h3>Ropidoxuridine Phase 2 Trial Gains Momentum</h3>The heart of Shuttle Pharma’s pipeline is <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/therapeutics/ropidoxuridine/">Ropidoxuridine</a> (IPdR), a novel radiation sensitizer currently in Phase 2 clinical trials for the treatment of glioblastoma. The aggressive brain cancer has limited treatment options and remains incurable. Shuttle’s approach aims to amplify the efficacy of radiation therapy while keeping side effects minimal.As of <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">May 8, 2025</a>, nearly 50% of the trial’s initial enrollment target had been met. Impressively, 84% of patients enrolled had completed all seven cycles of treatment. Trial sites—ranging from Georgetown University Medical Center to the Miami Cancer Institute—reported the drug was well tolerated, with toxicity scores not exceeding 2 on a 1-5 scale.Dr. Anatoly Dritschilo, who recently stepped down as Chairman and Chief Scientific Officer, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-fda-orphan-drug-nears-patient-enrollment-milestone-for-phase-2-clinical-trial/">said</a>, “If approved, we believe that Ropidoxuridine has the potential to redefine the standard approach for how to care for patients with glioblastoma.”Patients are being randomized into two dose cohorts—1,200 mg/day and 960 mg/day—to determine the optimal regimen. Once identified, an additional 14 patients will be enrolled at the best dose to reach statistical significance. The trial aims to complete enrollment later this year, with data readouts expected in 2026.Chris Cooper, Shuttle’s interim CEO, <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">commented</a>:<blockquote>With nearly 50% of patient enrollment achieved in the initial randomized portion and 84% of enrolled patients completing all seven cycles, the trial is advancing steadily at esteemed cancer centers. Ropidoxuridine has been well-tolerated and we have begun analyzing pharmacokinetic and pharmacodynamic samples to optimize dosing and response. Our goal is to complete enrollment later this year, with follow-up and data readouts anticipated in 2026.</blockquote>The U.S. FDA has granted Orphan Drug Designation to Ropidoxuridine, giving Shuttle potential marketing exclusivity if approved. Given that an estimated 800,000 U.S. cancer patients undergo radiation therapy annually—and 400,000 of those for curative purposes—Shuttle’s target market is sizable and growing.Also Read: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/5-minute-deep-dive-scorecard-is-shuttle-pharmaceuticals-nasdaq-shph-ready-for-a-massive-breakout/">5-Minute Deep Dive Scorecard: Is Shuttle Pharmaceuticals (NASDAQ: SHPH) Ready for a Massive Breakout?</a><h3>Innovation Extends Beyond the Clinic</h3>On May 15, 2025, Shuttle released a <a target="_blank" rel="noopener noreferrer nofollow" href="https://shuttlepharma.com/shuttle-pharma-provides-corporate-update/">corporate update</a> highlighting the company’s many recent developments. In addition to clinical progress, Shuttle has made strides in the diagnostics space. The company entered a sponsored research agreement with the University of California, San Francisco (UCSF) to develop a PSMA-targeted ligand for theranostic use in prostate cancer.Furthermore, Shuttle filed a <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-targets-prostate-cancer-with-psma-ligand-breakthrough/">provisional patent</a> titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.” The filing was developed with Dr. Alan Kozikowski, a medicinal chemist whose past work helped enable the development of Lantheus’ Pylarify and Novartis’ Pluvicto—two commercially successful radiopharmaceuticals.Shuttle’s recent underwritten <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/stocks/biotech/shuttle-pharma-closes-5-75-million-offering/">public offering</a> helped solidify its financial footing, with $4.5 million in cash and equivalents reported as of March 31, 2025. That cash will fund both the ongoing clinical trial and preclinical research efforts.<h3>Strengthened Leadership Amid Key Transitions</h3>While Scorsis’ arrival marks a new chapter, Shuttle has also seen notable exits. Dr. Dritschilo resigned from the Board and his role as CSO, while Michael Vander Hoek, the company’s VP of Regulatory, announced his retirement effective June 10.New board members Oleh Nabyt and Joseph Tung join Scorsis in reinforcing Shuttle’s governance and bringing expanded business and legal acumen to the table.<h3>Looking Ahead</h3>Shuttle Pharmaceuticals appears to be building momentum across multiple fronts—clinical, intellectual property, diagnostics, and leadership. With a new Chairman in place, promising mid-trial results, and a strengthened pipeline backed by a scientific pedigree, the company is drawing comparisons to past success stories, such as Lantheus Holdings and Novartis.Investors will watch closely as the Ropidoxuridine trial progresses toward full enrollment and data publication in 2026. If Shuttle can successfully deliver on its ambitions, it could play a major role in transforming radiation therapy for cancer patients worldwide.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/videos/shuttle-pharma-showcases-cancer-treatment-advancements-at-planet-microcap-vegas-2025/">This Biotech Stock Took The Center Stage at the Planet MicroCap Showcase: VEGAS 2025</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:invest@wealthyvc.com">invest@wealthyvc.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations

Others

George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Lantheus to Acquire Evergreen...

Peering Into Lantheus Holdings's Recent Short Interest

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players PR Newswire VANCOUVER...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Why Lantheus Holdings Stock Is Skyrocketing Today

Why Lantheus Holdings Stock Is Skyrocketing Today...

Evaluating Lantheus Holdings: Insights From 5 Financial Analysts

Latest Ratings for LNTH
 DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Jul 2021SVB LeerinkMaintainsOutperform May 2021Credit SuisseMaintainsNeutral
 View More Analyst Ratings for...

Interesting LNTH Put And Call Options For May 17th

Investors in Lantheus Holdings Inc (LNTH) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LNTH...

Lantheus Holdings (LNTH, $60.11) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

This is a Bullish indicator signaling LNTH's price could rise from here. Traders may explore going long the stock or buying call options...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

LNTH
Lantheus Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNTH News

LNTH Lantheus Holdings Inc